艾美疫苗(06660.HK):新冠病毒變異株(Omicron BA.5)mRNA疫苗(LVRNA012)國內保護效力研究取得主要結果
格隆匯6月1日丨艾美疫苗(06660.HK)發佈公吿,近日,集團的新型冠狀病毒變異株(Omicron BA.5)mRNA疫苗(LVRNA012)在中國國內開展的研究者發起的保護效力和安全性臨牀研究已完成關鍵性數據的期中分析並取得主要結果,最高保護率達到80.68%。
本研究旨在評價該疫苗在18週歲及以上人羣中加強接種1劑的保護效力、安全性和免疫原性。接種第7天后收集的新冠病例中絕大部分症狀為輕型,極個別為中型,該疫苗預防新冠病毒感染所致疾病的保護率為73.16%,95%置信區間下限54.24%,上限85.00%,這一結果遠高於新冠疫苗保護效力的國際標準(即保護率 ≥50%和95%置信區間下限≥30%)。
尤其值得注意的是2023年4月末以來,中國國內以XBB變異株流行為主(佔96%,來自GISAID監測數據)。該時期報吿的病例單獨計算保護率達到80.68%,95%置信區間下限55.98%,上限92.74%。這一結果提示,雖然2023年4月下旬以來國內主要流行株由BA.5.2和BF.7及其亞分支轉變為XBB及其亞分支,但是該疫苗的保護率並未降低,反而表現出更高的保護效力。僅從本次試驗數據上來看,該疫苗對XBB變異株展現出更優異的保護效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.